Editas Medicine在2026年美国基因与细胞治疗学会年会上公布新临床前数据,展示Edit-401作为高脂血症潜在疗法的进展

美股速递
May 14

Editas Medicine, Inc. (EDIT) 在2026年美国基因与细胞治疗学会年会上公布了新的临床前数据,这些数据展示了其研究性疗法Edit-401作为治疗高脂血症潜在方案的进展。报告内容突显了该疗法在临床前模型中的有效性与作用机制,为其后续的临床开发路径提供了支持依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10